Proteomics International Faces Pressure to Convert Medicare Pricing Into Revenue Growth
Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.
- US Medicare sets reimbursement price for PromarkerD at US$390.75
- PromarkerD and PromarkerEso launched in Australia with initial sales recorded
- New data shows OxiDx biomarker linked to improved racehorse performance
- Company confirms compliance with ASX continuous disclosure rules
- No undisclosed material information identified to explain recent trading
Context Behind the Price Movement
Proteomics International Laboratories Ltd (ASX, PIQ) has responded to an ASX price query following a notable increase in its share price and trading volume. The company confirmed that it is not aware of any undisclosed information that could explain the recent market activity. Instead, it pointed to a series of recent announcements that may have driven investor interest.
Medicare Reimbursement Boosts US Market Prospects
On 26 November 2025, the US Centers for Medicare & Medicaid Services (CMS) set the reimbursement price for Proteomics International’s next-generation PromarkerD test for diabetic kidney disease at US$390.75. This pricing decision is significant as Medicare and Medicaid collectively account for 42% of healthcare spending in the US, effectively underpinning the company’s US launch strategy. The CMS determination is expected to broaden patient access and strengthen discussions with private payers and strategic partners, potentially accelerating commercial uptake.
Advances in Biomarker Applications and Australian Market Entry
Proteomics International also highlighted new performance data for its OxiDx oxidative stress biomarker, which correlates with enhanced performance in Australian Thoroughbred racehorses. The data suggests that horses racing without oxidative stress were significantly more likely to place or win, underscoring OxiDx’s potential to improve performance management and welfare outcomes in the racing industry.
Additionally, the company has achieved clinical certification for its Australian diagnostics laboratory, enabling it to provide pathology testing for its precision diagnostic tests. Both PromarkerD and PromarkerEso have been launched in Australia, with initial sales already recorded, marking important commercial milestones.
Compliance and Market Communication
Proteomics International reaffirmed its compliance with ASX Listing Rules, particularly continuous disclosure obligations under Listing Rule 3.1. The company’s response to the ASX price query was authorised by senior management, reflecting its commitment to transparency and regulatory adherence.
While the company did not disclose any new material information beyond what has been publicly announced, the combination of Medicare reimbursement, product launches, and promising biomarker data likely contributed to the heightened investor interest and recent trading activity.
Bottom Line?
Proteomics International’s recent milestones have sparked market attention, but the true test will be translating these into sustained commercial success.
Questions in the middle?
- How quickly will Medicare reimbursement translate into meaningful US sales growth for PromarkerD?
- What are the competitive dynamics for PromarkerD and OxiDx in their respective markets?
- Can Proteomics International sustain momentum with further product launches or partnerships?
